Taiwan As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its COVID-19 vaccine, representing a debut on two fronts. Not only is this the first time a COVID-19 vaccine developed by…
Taiwan Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges Charles, could you start by introducing Medigen…
Array The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites the international life sciences com-munity to the island, the excitement was palpable. Foreign companies turned out in record numbers to…
Clinical trials The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative molecule PI-88. He also offers his perspective on the increasing synergies between Taiwan and China in the biotech sector. During our…
Medigen Biotechnology Corp. Medigen was created in 1999 and is a listed company. How did the vision for the company come about, and what was it that attracted today’s main shareholders to Medigen? Medigen was registered at the MOEA in 1999, but the company was actually established in 2000. In the beginning, the…
See our Cookie Privacy Policy Here